The BRI Blog

A competitive drug market strongly encourages companies to best their rivals by developing the next generation of life-saving therapies. This leads to lower prices without the harmful effects of government coercion.

If the government is going to spend enormous sums subsidizing health insurance, much better to give those funds to individuals and let them use the money to buy coverage of their choosing — or even pay for care directly.

The astounding expansion of Medicaid has made it harder for genuinely destitute people to get care.  That problem is only exacerbated when states flout federal laws to bring a growing number of illegal immigrants onto Medicaid’s rolls.

The 340B Drug Pricing Program was designed to help hospitals serving low-income communities with discounted drugs.

Like so many others, it has metastasized into a wildly expensive welfare program and, effectively, a profit center for well-off hospitals.

Each year that goes by without Congress changing how Medicare pays doctors is a year that deprives countless patients—especially seniors—timely access to care.

One one hand, the One Big Beautiful Bill July reconciliation package restores fiscal responsibility, tackles fraud, and empowers patients through direct primary care. But price controls, extensions to pandemic-era programs, and widespread fraud threaten to undermine all that progress.